INSTITUT CLAUDIUS REGAUD
Evaluation of Pain and Postoperative Nausea Vomiting Incidence in Outpatient Surgery at IUCT-Oncopole Hospital
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 200
- Registration Number
- NCT03669328
- Locations
- π«π·
Institut Claudius Regaud, Toulouse, Occitanie, France
FALCOn (Facteur AnthropoLogique Cancer Orl)
- Conditions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 206
- Registration Number
- NCT03663985
- Locations
- π«π·
Institut Claudius Regaud, Toulouse, Occitanie, France
Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy.
- Conditions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 65
- Registration Number
- NCT03627988
- Locations
- π«π·
Institut Bergonie, Bordeaux, France
π«π·Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients
- Conditions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 78
- Registration Number
- NCT03627026
- Locations
- π«π·
Chu Nantes, Nantes, France
π«π·Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France
Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 11
- Registration Number
- NCT03623646
- Locations
- π«π·
CHU Bordeaux, Bordeaux, France
π«π·Institut Universitaire du Cancer Toulouse (IUCT-O), Toulouse, France
π«π·Centre Jean Perrin, Clermont-Ferrand, France
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-Ξ± Status in Patients With Metastatic Breast Cancer HER2 + and ERΞ± Neg Treated With Trastuzumab + Pertuzumab + Taxane.
- Conditions
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 4
- Registration Number
- NCT03619044
- Locations
- π«π·
Centre Hospitalier Auch, Auch, France
π«π·Clinique Claude Bernard, Albi, France
π«π·Clinique Capio La Croix Du Sud, Quint-fonsegrives, France
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 520
- Registration Number
- NCT03514368
- Locations
- π«π·
Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France
π«π·Chu Rangueil, Toulouse, France
π«π·Hopital Larrey, Toulouse, France
Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 59
- Registration Number
- NCT03514381
- Locations
- π«π·
Institut Bergonie, Bordeaux, France
π«π·Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France
π«π·Institut Regional Du Cancer de Montpellier (Icm), Montpellier, France
Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 150
- Registration Number
- NCT03447483
- Locations
- π«π·
Institut Regional Du Cancer de Montpellier (Icm), Montpellier, France
π«π·Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France
π«π·CH ALBI, Albi, France
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
- Conditions
- Interventions
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 6
- Registration Number
- NCT03354962
- Locations
- π«π·
Chu Bordeaux, Bordeaux, France
π«π·Centre Oscar Lambret, Lille, France
π«π·CHU NICE, Nice, France